Using Xe MRI to Guide Radiation Therapy for Lung Cancer

Conditions

• Imaging Techniques

Eligibility Criteria

Sex

ALL

Age

18 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Xenon MRI — DRUG
  MRI with Xenon used for contrast
• Pulmonary Function Testing — DIAGNOSTIC_TEST
  Pulmonary function testing will include spirometry, lung volumes, DLCO and oscillometry
• Quality of Life Questionnaire — OTHER
  European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30+QLQ-LC29)
• Medical Research Council Dyspnea score — OTHER
  modified Medical Research Council Dyspnea score (mMRC Dyspnea)
• St. George's Respiratory Questionnaire — OTHER
  St. George's Respiratory Questionnaire (SGRQ)
• Blood Biomarkers — DIAGNOSTIC_TEST
  blood biomarkers of inflammation and injury (e.g. Angiopoetin-2, Interleukin-6, myofibroblast activity, BPD4)

Study Details

The purpose of this research study is to explore using MRI scans with xenon to better image lung function, how lung function changes after radiation therapy, and to guide radiation therapy away from parts of the lung that have good function. This project is foundational to performing additional studies to establish if novel MRI imaging can serve as a guidance tool for lung cancer radiation treatment.

Key Dates

Start date

Aug 30, 2025

Status verified

Dec 2025

Primary completion

Jan 31, 2027

Completion

Jan 31, 2027

Study Design

Enrollment

15 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Arms

• Experimental: Technical Development Arm
  Lung cancer patients who will undergo standard-of-care stereotactic body radiation therapy (SBRT).
• Experimental: Implementation Arm
  Lung cancer patients who will undergo SBRT plans that were functionally adapted to avoid highly functioning lung based on Xe MRI.

Primary Outcome Measure

The incidence of PFT evidence of radiation pneumonitis and lung function change on spirometry [ Time Frame: Baseline Visit, periprocedural, 1 month follow up visit, and 6 month follow up visit.. ]

Central Contacts

• Eric Bruening
  319-789-0806
  [email protected]

Locations (1)

Find similar trials in Iowa City, IA